Compare Dr. Reddys with Orchid Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs ORCHID PHARMA LTD - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB ORCHID PHARMA LTD DR. REDDYS LAB/
ORCHID PHARMA LTD
 
P/E (TTM) x 16.9 -0.5 - View Chart
P/BV x 3.2 0.1 2,744.7% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 DR. REDDYS LAB   ORCHID PHARMA LTD
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-19
ORCHID PHARMA LTD
Sep-13
DR. REDDYS LAB/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs2,875194 1,482.0%   
Low Rs1,88835 5,394.3%   
Sales per share (Unadj.) Rs930.2276.5 336.5%  
Earnings per share (Unadj.) Rs117.4-79.2 -148.2%  
Cash flow per share (Unadj.) Rs185.8-43.5 -427.5%  
Dividends per share (Unadj.) Rs20.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs844.453.9 1,565.6%  
Shares outstanding (eoy) m166.0770.45 235.7%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x2.60.4 618.2%   
Avg P/E ratio x20.3-1.4 -1,403.1%  
P/CF ratio (eoy) x12.8-2.6 -486.5%  
Price / Book Value ratio x2.82.1 132.9%  
Dividend payout %17.00-   
Avg Mkt Cap Rs m395,4968,067 4,902.9%   
No. of employees `00022.02.8 784.5%   
Total wages/salary Rs m33,5622,527 1,328.1%   
Avg. sales/employee Rs Th7,032.86,956.1 101.1%   
Avg. wages/employee Rs Th1,527.9902.5 169.3%   
Avg. net profit/employee Rs Th887.7-1,993.0 -44.5%   
INCOME DATA
Net Sales Rs m154,48219,477 793.2%  
Other income Rs m3,375407 828.8%   
Total revenues Rs m157,85719,884 793.9%   
Gross profit Rs m31,7821,103 2,882.5%  
Depreciation Rs m11,3482,519 450.5%   
Interest Rs m8895,227 17.0%   
Profit before tax Rs m22,920-6,236 -367.5%   
Minority Interest Rs m020 0.0%   
Prior Period Items Rs m4380-   
Extraordinary Inc (Exp) Rs m0511 0.0%   
Tax Rs m3,858-125 -3,081.5%   
Profit after tax Rs m19,500-5,580 -349.4%  
Gross profit margin %20.65.7 363.4%  
Effective tax rate %16.82.0 838.4%   
Net profit margin %12.6-28.7 -44.1%  
BALANCE SHEET DATA
Current assets Rs m111,10111,014 1,008.7%   
Current liabilities Rs m58,97332,060 183.9%   
Net working cap to sales %33.7-108.1 -31.2%  
Current ratio x1.90.3 548.4%  
Inventory Days Days7995 83.6%  
Debtors Days Days9434 280.7%  
Net fixed assets Rs m101,24529,440 343.9%   
Share capital Rs m830705 117.8%   
"Free" reserves Rs m139,4062,043 6,824.9%   
Net worth Rs m140,2363,800 3,690.5%   
Long term debt Rs m22,0009,018 244.0%   
Total assets Rs m224,65646,510 483.0%  
Interest coverage x26.8-0.2 -13,867.9%   
Debt to equity ratio x0.22.4 6.6%  
Sales to assets ratio x0.70.4 164.2%   
Return on assets %9.1-0.8 -1,194.1%  
Return on equity %13.9-146.9 -9.5%  
Return on capital %14.9-3.7 -400.2%  
Exports to sales %037.9 0.0%   
Imports to sales %022.6 0.0%   
Exports (fob) Rs mNA7,378 0.0%   
Imports (cif) Rs mNA4,406 0.0%   
Fx inflow Rs m88,6737,513 1,180.2%   
Fx outflow Rs m19,1045,649 338.2%   
Net fx Rs m69,5691,865 3,731.2%   
CASH FLOW
From Operations Rs m28,7041,682 1,706.8%  
From Investments Rs m-7,727-9,860 78.4%  
From Financial Activity Rs m-21,3266,644 -321.0%  
Net Cashflow Rs m-314-1,535 20.5%  

Share Holding

Indian Promoters % 25.5 32.3 78.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 4.6 117.4%  
FIIs % 35.3 3.3 1,069.7%  
ADR/GDR % 18.5 4.6 402.2%  
Free float % 15.3 55.3 27.7%  
Shareholders   75,885 84,811 89.5%  
Pledged promoter(s) holding % 0.0 54.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   J.B.CHEMICALS  NOVARTIS  ALEMBIC PHARMA  WYETH LTD  GSK PHARMA  

Compare DR. REDDYS LAB With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 72 Points Lower; Capital Goods and Auto Stocks Witness Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their day marginally lower.

Related Views on News

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

ORCHID PHARMA LTD Announces Quarterly Results (2QFY19); Net Profit Up 67.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended September 2018, ORCHID PHARMA LTD has posted a net profit of Rs 231 m (up 67.1% YoY). Sales on the other hand came in at Rs 1 bn (down 31.9% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

ORCHID PHARMA LTD Announces Quarterly Results (4QFY18); Net Profit Up 50.8% (Quarterly Result Update)

Aug 24, 2018 | Updated on Aug 24, 2018

For the quarter ended March 2018, ORCHID PHARMA LTD has posted a net profit of Rs 924 m (up 50.8% YoY). Sales on the other hand came in at Rs 2 bn (down 24.0% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Nov 18, 2019 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS